GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions

Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation

Interventions

DRUG

GH21

GH21 Capsules, Oral Drug Specification: 3mg/capsule; 10mg/capsule

DRUG

D-1553

D-1553 Film-coated Tablets, Oral Drug Sepcification: 200mg/tablet

All Listed Sponsors

collaborator

Zhejiang Cancer Hospital

OTHER

lead

Suzhou Genhouse Bio Co., Ltd.

OTHER

NCT06435455 - GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors | Biotech Hunter | Biotech Hunter